O'Reilly R A
Clin Pharmacol Ther. 1981 Mar;29(3):332-6. doi: 10.1038/clpt.1981.45.
To evaluate the interaction of disulfiram with the separated enantiomorphs of racemic warfarin, seven normal subjects received single doses of R-warfarin (1.5 mg/kg body weight) and S-warfarin (0.75 mg/kg body weight) with and without a daily dose of disulfiram 250 mg, beginning 3 days before the warfarin dose and continuing for the duration of the hypoprothrombinemia. Disulfiram augmented the S-warfarin hypoprothrombinemia (p less than 0.001) but not that of R-warfarin (p less than 0.10). Disulfiram did not alter plasma concentrations of either R-warfarin (p greater than 0.10) or S-warfarin (p greater than 0.40). Disulfiram augments the hypoprothrombinemia of racemic warfarin stereoselectively by interacting primarily with S-warfarin. As disulfiram did not change the plasma concentrations of either enantiomorph, it may augment the anticoagulant effect of racemic warfarin by directly affecting the hepatic mechanism responsible for the hypoprothrombinemia.
为评估双硫仑与消旋华法林分离对映体的相互作用,7名正常受试者接受了单剂量的R-华法林(1.5毫克/千克体重)和S-华法林(0.75毫克/千克体重),分别在服用华法林前3天开始,每日服用250毫克双硫仑,持续至低凝血酶原血症期。双硫仑增强了S-华法林引起的低凝血酶原血症(p<0.001),但对R-华法林引起的低凝血酶原血症无增强作用(p<0.10)。双硫仑未改变R-华法林(p>0.10)或S-华法林(p>0.40)的血浆浓度。双硫仑主要通过与S-华法林相互作用,立体选择性地增强消旋华法林的低凝血酶原血症。由于双硫仑未改变任一纯对映体的血浆浓度,它可能通过直接影响导致低凝血酶原血症的肝脏机制来增强消旋华法林的抗凝作用。